Key takeaways: Using STRIDE with transarterial chemoembolization significantly improved PFS. Formal OS analyses have not been performed, though data suggest a trend toward improved survival. CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3 study.
Daneng Li
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Daneng
Contact Daneng, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack